Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086841 | 1.00 | MEN1 (0.41) | MEN1POLBKMT2AMAPK14MTOR | |
| SCHEMBL6088653 | 0.93 | ALDH1A1 (0.38) | MEN1POLBKMT2APAK1NTRK1 | |
| SCHEMBL6088655 | 0.93 | ALDH1A1 (0.38) | MEN1POLBKMT2APAK1NTRK1 | |
| SCHEMBL6086835 | 0.92 | LMNA (0.37) | MEN1KMT2AMAPK14MTORNTRK1 | |
| SCHEMBL6086825 | 0.92 | LMNA (0.37) | MEN1KMT2AMAPK14MTORNTRK1 | |
| SCHEMBL6086446 | 0.86 | MAPK14 (0.44) | MEN1KMT2AMAPK14LRRK2ADORA2A | |
| SCHEMBL6086453 | 0.86 | MAPK14 (0.44) | MEN1KMT2AMAPK14LRRK2ADORA2A | |
| SCHEMBL6086980 | 0.85 | MAPK1 (0.49) | MEN1POLBKMT2APARP1 | |
| SCHEMBL6086987 | 0.85 | MAPK1 (0.49) | MEN1POLBKMT2APARP1 | |
| SCHEMBL14725076 | 0.85 | NTRK1 (0.33) | PAK1LRRK2NTRK1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490356-B1 | (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-7060844-B2 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | MEN1 3222/4885POLB 3698/4885KMT2A 1161/4885 |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | MEN1 3309/4885POLB 3631/4885KMT2A 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.